Business Context and Reporting Period
Company: SIGA Technologies, Inc.
Filing Type: Form 8-K (Current Report)
Reporting Date: December 31, 2012
Event: Entry into a Material Definitive Agreement and Creation of a Direct Financial Obligation.
Key Financial Metrics and Debt Structure
The filing details a new financing arrangement with General Electric Capital Corporation (GECC) as the lender and agent.
- Term Loan: $5 million drawn on December 31, 2012, with a fixed interest rate of 9.85% per annum.
- Revolving Facility: $7 million available upon meeting a threshold of approximately $43 million in eligible receivables. The minimum floating interest rate is 6.75% per annum.
- Term: Three years.
- Collateral: First priority lien on all existing and after-acquired property, excluding specific assets related to the ST-246 product (Tecovirimat) and related intellectual property.
Material Changes and Covenants
This filing represents a material change in the company's capital structure through the incurrence of new debt. Key terms include:
- Prepayment Premiums: Applicable if the Term Loan or Revolver is prepaid or terminated early. Rates are 3% in year one, 2% in year two, and 1% in year three.
- Mandatory Prepayment: Required if an exclusive license exists on all or any part of the ST-246 Product.
- Covenants: The agreement includes customary representations, warranties, negative covenants, and affirmative covenants.
Guidance, Risks, and Contingencies
The filing does not provide forward-looking financial guidance or management commentary regarding future revenue or profit. However, it highlights specific risks and contingencies:
- Liquidity Contingency: Access to the $7 million revolving facility is contingent on the company generating eligible receivables exceeding $43 million.
- Asset Exclusion Risk: The company's primary drug candidate (ST-246/Tecovirimat) and related IP are excluded from the collateral pool, which may impact future financing options secured by these assets.
- Default Risk: The loans are subject to customary events of default.
Investor Verification Checklist
- Verify the current status of eligible receivables to determine if the $7 million revolving facility is currently accessible.
- Review the full Loan and Security Agreement (Exhibit 10.1) for specific negative covenants that may restrict future operations or capital raising.
- Monitor the development and licensing status of the ST-246 product, as an exclusive license could trigger mandatory prepayment of the debt.
- Assess the company's cash burn rate against the $5 million term loan to evaluate runway without additional financing.